ITGAM and neoplasm: In addition, CD11b-positive tumor-infiltrating NK cells, macrophages, and granulocytes were significantly recruited into tumor foci upon trastuzumab treatment (25.3 ± 4.2% vs. 14.8 ± 2.6%, P = 0.003) (Figure 3b and d).